Kither Biotech

Turin, Italy· Est. 2013

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $37.5M

Overview

Kither Biotech is a private, clinical-stage company developing inhaled therapies for rare respiratory diseases with high unmet need, notably cystic fibrosis and idiopathic pulmonary fibrosis. Its lead asset, KIT2014, an orphan drug-designated dual PDE3/4 inhibitor peptide, successfully completed Phase 1 in 2025, with Phase 2 planned for 2026. The company has raised significant venture capital, including a €5.6M Series A and an €18.5M Series B in 2022, to advance its pipeline and is built on strong academic roots from the University of Turin.

Cystic FibrosisIdiopathic Pulmonary FibrosisChronic Obstructive Pulmonary DiseaseNon-Cystic Fibrosis Bronchiectasis

Technology Platform

Platform focused on modulating PI3K and cAMP signaling pathways using proprietary peptides and small-molecule inhibitors, delivered via inhalation for targeted lung therapy.

Funding History

Total raised:$37.5M

Series B$25MClaris VenturesJun 15, 2022

Series A$10MClaris VenturesJun 15, 2020

Seed$2.5MIndaco Venture PartnersJun 15, 2018

Opportunities

The high unmet need in IPF and the adjunctive treatment potential in CF present significant market opportunities.

Orphan drug designations provide regulatory and commercial advantages, and the link between severe COVID-19 and pulmonary fibrosis may expand the addressable patient population for KITCL27.

Risk Factors

The company faces clinical trial failure risk with its lead asset, high dependency on a single program (KIT2014), and intense competition in both CF and IPF markets.

As a pre-revenue private company, it also carries financing and dilution risk.

Competitive Landscape

In CF, Kither competes against Vertex's dominant CFTR modulators and other companies developing correctors, potentiators, and anti-inflammatory agents. In IPF, it faces competition from approved anti-fibrotics (pirfenidone, nintedanib) and a pipeline of novel anti-fibrotic and anti-inflammatory agents from larger biopharma firms.